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ABSTRACT
This study explored the possibility of combining
direct inoculation of tube coagulase and DNase
tests, and the VITEK2 system, from BACTEC
blood culture bottles in order to achieve rapid
identiﬁcation and susceptibility testing of Staphy-
lococcus aureus. All isolates were identiﬁed
correctly as S. aureus or coagulase-negative sta-
phylococci (CNS). Antimicrobial susceptibility
testing with the VITEK2 system gave 99.6%
correct category agreement, with 0.1% very major
errors and 0.3% minor errors among S. aureus
isolates, and 97.4% correct category agreement,
with 0.9% very major errors and 1.7% minor
errors among CNS isolates. The results suggested
that direct identiﬁcation and susceptibility testing
is sufﬁciently accurate for immediate reporting.
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Staphylococcus aureus is currently the most com-
mon cause of infections among hospitalised
patients [1], and misidentiﬁcation can result in
unwarranted broad-spectrum empirical antibiotic
therapy or a costly search for other pathogens.
Shortening the turn-around time for microbiolo-
gical analysis can lead to a signiﬁcant reduction in
patient morbidity, patient mortality and cost,
particularly for patients with septicaemia [2,3].
The aim of the present study was to test the
accuracy of direct testing of blood cultures to
minimise the time required to generate an iden-
tiﬁcation and susceptibility result.
Data were collected from April to June 2004.
During this period, every ﬁrst blood culture pos-
itive for staphylococcal-like Gram-positive cocci
(n = 70) was included in the study. All blood
cultures containing Gram-negative enteric bacilli,
orwithpolymicrobialmorphology,were excluded.
In standard testing procedures, a small volume
of blood culture (BACTEC; Becton Dickinson,
Erembodegem-Aalst, Belgium) was inoculated on
to a combination of agar plates for aerobic and
anaerobic microorganisms. After overnight incu-
bation, colonies of suspected staphylococci were
tested by tube coagulase tests with 0.5 mL of
rabbit plasma with EDTA (Becton Dickinson
Biosciences, Sparks, MD, USA) and DNase tests
(Oxoid, Haarlem, The Netherlands). For antimi-
crobial susceptibility testing (AST), the VITEK2
system (bioMe´rieux, Marcy l’E´toile, France) was
used with AST-P523 cards, according to standard
VITEK2 procedures. For direct testing, serum
separator tubes (BD Vacutainer Systems; Becton
Dickinson) were inoculated with 10 mL of posit-
ive blood culture and centrifuged at 1300 g for
10 min. With a cotton swab, the ﬁlm of bacteria on
top of the gel layer was removed and used to
inoculate tube coagulase and DNase tests, as well
as the VITEK2 system.
For both direct and standard identiﬁcation,
positive tube coagulase and DNase tests were
interpreted as S. aureus, while negative tube
coagulase and DNase tests were interpreted as
coagulase-negative staphylococci (CNS). MICs
determined by both methods identiﬁed the cate-
gory of microbial susceptibility as susceptible,
intermediate or resistant according to NCCLS
interpretative criteria [4]. A very major error was
recorded if the result of direct testing was ‘sus-
ceptible’ and the result of standard testing was
‘resistant’; a major error was recorded if the
opposite was the case. All other errors were
considered minor.
Identiﬁcation of all S. aureus and CNS isolates by
standard and direct inoculation of tube coagulase
and DNase tests was in agreement. Two cultures
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failed to grow after direct inoculation; therefore, 68
specimens (37 S. aureus and 31 CNS) were eligible
for AST. In total, 1428 MIC determinations (777
S. aureus and 651 CNS) were made by the direct
and standard methods. Overall, 99.6% of VITEK2
AST results were in agreement for S. aureus
isolates. Minor discrepancies occurred for nitro-
furantoin, yielding an overall minor error rate of
0.3% (2 of 777). One very major error occurred for
benzylpenicillin (0.1%; 1 of 777). In total, 97.4% of
VITEK2 AST results were in agreement for isolates
of CNS. Minor errors occurred for nitrofurantoin
(n = 2), gentamicin (n = 1), tobramycin (n = 3),
kanamycin (n = 1), pristinamycin (n = 1) and fus-
idic acid (n = 3), yielding an overall minor error
rate of 1.7% (11 of 651). Verymajor errors occurred
for benzylpenicillin (n = 1), oxacillin (n = 2), trim-
ethoprim–sulphamethoxazole (n = 2) and kana-
mycin (n = 1), yielding an overall major error rate
of 0.6% (6 of 651). Table 1 outlines the results of
direct AST results for a selection of clinically
relevant antibiotics.
Direct inoculation of tube coagulase and
DNase tests gave no false-positive or false-
negative results. Previous studies have investi-
gated the clinical performance of rapid tube
coagulase tests for direct identiﬁcation of S.
aureus from positive blood cultures. Tube coag-
ulase read at 4 h was 84.1% sensitive and 100%
speciﬁc [5]. After 24 h, nine of 11 isolates became
tube coagulase-positive, while two remained
negative. However, Cooke and Jenkins [6] repor-
ted favourable performance of the 2-h direct tube
coagulase test and demonstrated no signiﬁcant
difference in performance if the test was read at
2, 6 or 24 h.
The Food and Drug Administration (FDA) has
established minimal performance characteristics
to assess AST [7]. These guidelines indicate that
category agreement should be > 90%, major
errors should be < 3%, and very major errors
should be < 1.5%. In the present study, AST
determination of blood cultures positive for
staphylococci by direct inoculation of the VITEK2
system performed better than these guidelines.
Howard et al. [8] examined the accuracy of direct
AST from staphylococci-positive blood culture
bottles using VITEK1. The only oxacillin-resistant
S. aureus isolate was not detected using this
procedure, and 20.4% of oxacillin-resistant iso-
lates of CNS were missed.
In The Netherlands, most S. aureus isolates are
susceptible to clinically relevant antibiotics such
as oxacillin, rifampicin and clindamycin, and it is
therefore difﬁcult to verify the ability of the direct
method to detect resistance. Kerremans et al. [9]
evaluated AST results obtained by direct inocu-
lation of VITEK2 cards from positive BACTEC
cultures. In total, 318 (75 S. aureus and 243 CNS)
specimens from 169 patients were tested in 6042
antibiotic–isolate combinations. Correct category
agreement among all staphylococcal isolates was
96%. The numbers of very major, major and
minor errors were 73 (4.5% of resistant strains), 32
(0.8% of susceptible strains) and 106 (1.8%),
respectively. In contrast to the present study,
most (84%) very major errors occurred with
trimethoprim–sulphamethoxazole.
In conclusion, the use of tube coagulase and
DNase tests for direct identiﬁcation of staphylo-
cocci from positive blood culture broths is an
inexpensive and reliable method for identifying
S. aureus in routine laboratory practice. The direct
AST method is reliable for immediate reporting,
according to FDA guidelines. However, a collec-
tion of S. aureus isolates susceptible to most
clinically relevant antibiotics was examined.
Therefore, direct AST cannot replace standard
methods without further evaluation and valid-
ation in areas with higher levels of resistance
among S. aureus isolates.
Table 1. Performance of direct susceptibility testing of
staphylococci compared to the standard method for a
range of clinically relevant antibiotics
Microorganism
and antimicrobial agents
% of suscept-
ible isolates No. of errors
CA (%)S I R VME ME mE
Staphylococcus aureus (n = 37)
Clindamycin 100 0 0 0 0 0 100
Erythromycin 100 0 0 0 0 0 100
Gentamicin 100 0 0 0 0 0 100
Oﬂoxacin 100 0 0 0 0 0 100
Oxacillin 100 0 0 0 0 0 100
Rifampicin 100 0 0 0 0 0 100
Teicoplanin 100 0 0 0 0 0 100
Trimethoprim–sulphamethoxazole 100 0 0 0 0 0 100
Vancomycin 100 0 0 0 0 0 100
Coagulase-negative staphylococci (n = 31)
Clindamycin 77.4 3.2 19.4 0 0 0 100
Erythromycin 67.7 0 32.3 0 0 0 100
Gentamicin 87.1 4.2 8.7 0 0 1 96.8
Oﬂoxacin 74.2 0 25.8 0 0 0 100
Oxacillin 38.7 0 61.3 2 0 0 93.5
Rifampicin 93.5 0 6.5 0 0 0 100
Teicoplanin 96.8 3.2 0 0 0 0 100
Trimethoprim–sulphamethoxazole 83.9 0 16.1 2 0 0 93.5
Vancomycin 100 0 0 0 0 0 100
S, susceptible; I, intermediate; R, resistant; VME, very major error; ME, major error;
mE, minor error; CA, category agreement.
Research Notes 85
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12, 81–95
REFERENCES
1. Archer GL. Staphylococcus aureus: a well-armed pathogen.
Clin Infect Dis 1998; 26: 1179–1181.
2. Barenfanger J, Drake C, Kacich G. Clinical and ﬁnancial
beneﬁts of rapid bacterial identiﬁcation and antimicrobial
susceptibility testing. J Clin Microbiol 1999; 37: 1415–1418.
3. Doern GV, Vautour R, Gaudet M, Levy B. Clinical impact of
rapid in vitro susceptibility testing and bacterial identiﬁ-
cation. J Clin Microbiol 1994; 32: 1757–1762.
4. National Committee for Clinical Laboratory Standards.
Methods for dilution antimicrobial susceptibility tests for bacteria
that grow aerobically, 6th edn. Approved standard M7-A6.
Wayne, PA: NCCLS, 2002.
5. Chapin K, Musgnug M. Evaluation of three rapid methods
for the direct identiﬁcation of Staphylococcus aureus from
positive blood cultures. J Clin Microbiol 2003; 41: 4324–4327.
6. Cooke RP, Jenkins CT. Comparison of commercial slide
agglutination kits with a tube coagulase test for the rapid
identiﬁcation of Staphylococcus aureus from blood culture.
J Clin Pathol 1997; 50: 164–166.
7. Thornsberry C. Automated procedures for antimicrobial
susceptibility tests. In: Lennette EH, Balows A, Hausler WJ,
Shadomy HJ, eds. Manual of clinical microbiology, 4th edn.
Washington, DC: American Society for Microbiology, 1985;
1015–1018.
8. Howard WJ, Buschelman BJ, Bale MJ, Pfaller MA, Koontz
FP, Jones RN. Vitek GPS card susceptibility testing accuracy
using direct inoculation from BACTEC 9240 blood culture
bottles. Diagn Microbiol Infect Dis 1996; 24: 109–112.
9. Kerremans JJ, Goessens WH, Verbrugh HA, Vos MC.
Accuracy of identiﬁcation and susceptibility results by
direct inoculation of Vitek 2 cards from positive BACTEC
cultures. Eur J Clin Microbiol Infect Dis 2004; 23: 892–898.
RESEARCH NOTE
Antimicrobial susceptibility patterns of
Haemophilus inﬂuenzae and Streptococcus
pneumoniae isolates in a Beirut general
university hospital between 2000 and 2004
Z. Daoud1, A. Cocozaki2 and N. Hakime3
1University of Balamand and Clinical Microbio-
logy Laboratory of the Saint George University
Hospital, 2University of Balamand and 3Labor-
atory Medicine Department of the Saint George
University Hospital, Beirut, Lebanon
ABSTRACT
Susceptibility patterns of Streptococcus pneumoniae
and Haemophilus inﬂuenzae collected over a 5-year
period in a Beirut general university hospital
were studied. Only 40.6–50% of S. pneumoniae
isolates were susceptible to penicillin G. Suscep-
tibility to clindamycin and erythromycin de-
creased from 94.1% and 89.7%, respectively, in
2000 to 75% and 71.9%, respectively, in 2004. All
isolates were susceptible to ceftriaxone, ciproﬂ-
oxacin and vancomycin. For H. inﬂuenzae, no
resistance was observed to amoxycillin-clavula-
nate, ceftriaxone, ciproﬂoxacin and rifampicin,
with >92% of isolates showing susceptibility to
cefuroxime, chloramphenicol, erythromycin and
tetracycline. The proportion of b-lactamase-posit-
ive isolates varied between 22.7 and 30.8%.
Keywords Antimicrobial susceptibility, b-lactamase
production, Haemophilus inﬂuenzae, penicillin-non-
susceptible pneumococci, resistance, Streptococcus
pneumoniae
Original Submission: 28 March 2005; Revised Sub-
mission: 1 June 2005; Accepted: 14 June 2005
Clin Microbiol Infect 2006; 12: 86–90
10.1111/j.1469-0691.2005.01303.x
Streptococcus pneumoniae and Haemophilus inﬂuen-
zae are among the bacteria isolatedmost frequently
from community-acquired respiratory tract infec-
tions [1–3]. Global penicillin resistance rates for
S. pneumoniae range from 5.8 to 54% [4], and
resistance to macrolides and quinolones is also
increasing [4,5]. Similarly, up to 40% of H. inﬂuen-
zae isolates now produce b-lactamase [6–8]. Con-
sequently, there is a need to survey national and
local changes in antimicrobial susceptibility pat-
terns in order to monitor the increase in resistance,
provide better therapy for patients, and maintain
the effectiveness of available drugs. In Lebanon,
information concerning antimicrobial susceptibil-
ity patterns remains scarce, and is limited to a few
hospitals and health centres where a handful of
studies have been conducted [9,10]. The present
report provides data concerning the susceptibility
proﬁles of S. pneumoniae and H. inﬂuenzae isolates
during a 5-year period at St. George Hospital,
Beirut, which is a 400-bed university medical
centre with 10 000–12 000 patients per year.
Between 1 January 2000 and 31 December 2004,
248 isolates of S. pneumoniae and 326 isolates of
H. inﬂuenzaewere collected prospectively. A labor-
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